Extended Data Fig. 6: Evaluation of CD8 and LAG-3 Biomarkers in Baseline and Recurrent Tumors. | Nature Medicine

Extended Data Fig. 6: Evaluation of CD8 and LAG-3 Biomarkers in Baseline and Recurrent Tumors.

From: Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial

Extended Data Fig. 6

a, CD8 and LAG-3 expression overall in baseline vs early recurrent tumors. b, Baseline expression of CD8 and LAG-3 in patients who did not have a recurrence vs those who had an early recurrence (prior to the minimum follow-up of 23.4 months). a, Box plot of screening/baseline versus recurrent CD8% and LAG3% in pooled treatment arms. The figure shows each biomarker, visit, and frequency of patients below and above the 1% cutoff. b, Negative(n) indicates number of patients with <1% immunohistochemistry and N indicates number of patients with immunohistochemistry. Box plot shows 25%, 50% and 75% quartiles and statistical tests are two-sided Wilcoxon with no multiple comparisons.CD, cluster of differentiation; LAG-3, lymphocyte activation gene 3.

Back to article page